Central nervous system progression during systemic response to trastuzumab, humanized anti-HER-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer

Breast Journal

Volumn 9, Issue 2, 2003, Pages 116-119

  Lindrud, Susan ^b   Orlick, Michelle ^b   Barnard, Nicola ^a,b   Hait, William N ^a,b   Toppmeyer, Deborah L ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Blood brain barrier; Breast cancer; Paclitaxel; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; ONCOPROTEIN; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; ONCOGENE NEU; PROGNOSIS; TREATMENT FAILURE; BREAST TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CEREBELLUM TUMOR; DRUG EFFECT; FATALITY; METASTASIS; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBELLAR NEOPLASMS; FATAL OUTCOME; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; RECEPTOR, ERBB-2; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0037827786     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2003.09214.x     Document Type: Article

References (8)

1. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:376a.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998;17:377a.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
4. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cell transfected with HER2/neu. Breast Cancer Res Treat 1992;24:85-95.
5. Blanco AR, Laurentis J, Carlomagno C, et al. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erbB-2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 1998;17:373a.
6. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-66.
7. Rowinsky EK, Burke PJ, Karp JE, Ettinger DS, Tucker RW, Donehower RC. Phase I study of taxol in refractory adult acute leukemia. Proc Am Assoc Cancer Res 1992;33:518.
8. Pestalozze BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18:2349-51.